- Details
- Weill Cornell is leading a randomized Phase II trial of salvage radiation therapy for prostate cancer in four weeks versus five days. The purpose of this trial is to compare the side effects of longer and shorter courses of radiation. Five days of treatment is a new option currently being studied in this trial with real-time MRI guidance. Related Content: ClinicalTrials.gov Identifier: NCT04422132...
|
- Details
- This video presents a study on a novel treatment approach for intermediate risk prostate cancer. The Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) study investigates the combination of radiation therapy and irreversible electroporation (IRE). Advanced imaging techniques, such as MRI and PSMA PET, help doctors identify aggressive and less aggressiv...
|
- Details
- The NRG-GU 010 phase III trial, known as Guidance, aims to optimize treatment strategies for prostate cancer based on the Decipher risk score. This score evaluates the tumor's potential for spreading, enabling personalized therapy selection. For patients with low risk scores, the trial compares radiation therapy alone to the standard approach of radiation therapy combined with hormone therapy (and...
|
- Details
- The NRG-GU 010 phase III trial, known as Guidance, aims to optimize treatment strategies for prostate cancer based on the Decipher risk score. This score evaluates the tumor's potential for spreading, enabling personalized therapy selection. For patients with low risk scores, the trial compares radiation therapy alone to the standard approach of radiation therapy combined with hormone therapy (and...
|
- Details
- The NRG-GU 010 phase III trial, known as Guidance, aims to optimize treatment strategies for prostate cancer based on the Decipher risk score. This score evaluates the tumor's potential for spreading, enabling personalized therapy selection. For patients with low risk scores, the trial compares radiation therapy alone to the standard approach of radiation therapy combined with hormone therapy (and...
|
- Details
- In this trial, Weill Cornell Medicine is investigating the safety and feasibility of a shorter course of radiation therapy for men with low or intermediate risk prostate cancer. The trial compares the effectiveness of MRI-guided adaptive radiotherapy delivered in either two or five treatment days. The goal of the trial is to benefit future prostate cancer patients by increasing convenience, reduci...
|
- Details
- Neeraj Agarwal joins Alicia Morgans to discuss the TALAPRO-3 trial, a phase III trial for patients with metastatic hormone-sensitive prostate cancer with DNA repair gene-related alterations or homologous recombination repair gene alterations in the tumors. The trial is ongoing, and accrual is expected to be completed soon. Ultimately, the trial aims to comprehensively assess efficacy, safety, and...
|
- Details
- At the 2022 EAU meeting, Declan Murphy presented the initial results of LuTectomy, a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to radical prostatectomy. Biochemical recurrence rates remain very high for men undergoing either surgery or radiotherapy for localized prostate cancer and no neoadjuvant strategies have succeeded this far in changing that. In...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the article published in the Journal of Nuclear Medicine reporting on the first retrospective data on the detection efficacy and potential impact of 18F-rhPSMA-7.3 on clinical management in a homogeneous cohort of patients with biochemical recurrence after radical prostatectomy, and prior to any salvage therapy. 18F-rhPSMA-7.3 is under investigation...
|
- Details
- Joining Alicia Morgans is Mark Markowski to discuss the results of a phase Ib/II study of the oral agent sabizabulin, also known as VERU-111. There is an unmet need for additional therapies for men with metastatic castration-resistant prostate cancer (mCRPC). Dr. Markowski shares findings from this study presented at GU ASCO 2022 including recommended phase two dose, what they found in terms of th...
|
